| 濮正平,费玉娥,林勇,夏江明.奥卡西平与通窍活血汤治疗瘀血内阻型血管性痴呆患者激越行为的疗效比较[J].浙江中西医结合杂志,2014,24(8): |
| 奥卡西平与通窍活血汤治疗瘀血内阻型血管性痴呆患者激越行为的疗效比较 |
| Treatment of Vascular Dementia Patients with Agitation of Blood Stagnation Syndrome by Oxcarbazepine And Tongqiaohuoxue Decoction Separately: An Efficacy Comparison |
| 投稿时间：2014-01-17 修订日期：2014-02-10 |
| DOI： |
| 中文关键词: 奥卡西平 通窍活血汤 瘀血内阻型 血管性痴呆 激越行为 |
| 英文关键词:Oxcarbazepine, Tongqiaohuoxue Decoction, blood stagnation syndrome, vascular dementia, agitation |
| 基金项目:2012桐乡市科技计划项目（编号：201203159） |
|
| 摘要点击次数: 2077 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 观察奥卡西平与通窍活血汤治疗瘀血内阻型血管性痴呆患者激越行为的不同疗效。 方法 将70例伴有激越行为的瘀血内阻型血管性痴呆患者随机分为研究组(单用奥卡西平治疗)和对照组(单用通窍活血汤治疗),每组35例,在治疗前及治疗的2、4、8周末分别采用简易智能状态检查量表(MMSE)、痴呆行为量表(BEHAVE-AD)、日常生活能力量表(ADL)等进行疗效评定,并记录不良反应的发生情况。 结果 所有患者均完成研究,无脱落病例。研究组患者治疗2周后的显效率高于对照组(P<0.05),而治疗8周后对照组患者的显效率高于研究组(P<0.05)；在治疗后第2周,研究组患者的BEHAVE-AD量表总分及攻击行为因子分低于对照组患者(P<0.05),而治疗8周后对照组患者的BEHAVE-AD量表总分及攻击行为因子分低于研究组患者(P<0.05或P<0.01)；对照组患者治疗8周后的MMSE量表总分高于研究组(P<0.05)而其ADL量表总分低于研究组(P<0.05)；治疗期间,对照组患者的“过度镇静”及“认知功能进行性下降”发生率均低于研究组(P<0.05)。 结论 在治疗瘀血内阻型血管性痴呆患者的激越行为方面,奥卡西平起效快,急性期疗效优于通窍活血汤；而后者起效较慢,但疗效相对稳定持久,且有利于改善患者的认知功能,副反应相对较轻。 |
| 英文摘要: |
| ABSTRACT Objective To compare the efficacy of Oxcarbazepine and Tongqiaohuoxue Decoction (TQHXD) in treating vascular dementia (VD) patients with agitation of blood stagnation (BS) syndrome. Methods 70 VD patients with agitation of BS were randomly assigned to the experimental group (Oxcarbazepine only) and the control group (TQHXD only), 35 cases in each group. Empirical Behavioral Rating Scale (BEHAVE-AD), Mini-mental State Examination (MMSE) and Activity of Daily Living Scale (ADL) were used before treatment, and at the weekend of the 2nd, 4th and 8th week, respectively. The adverse reactions were also recorded through the treatment. Results All the patients completed the trial. At the end of the 2nd week of the treatment the success rate in experimental group was higher than that in control group (P<0.05), while the success rate in control group at the end of the 8th week was higher than that in experimental group (P<0.05). At the end of the 2nd week of the treatment the scores of BEHAVE-AD and aggressive behavior factor in experimental group were lower than that in control group (P<0.05), while the scores in control group at the end of the 8th week were lower than that in experimental group (P<0.05, P<0.01). At the end of the 8th week of the treatment the score of MMSE in control group was higher than that in experimental group (P<0.05), while its score of ADL was lower than experimental groups’ (P<0.05). The rates of “excessive sedation” and “cognitive function being declining” in control group were lower than that in experimental group (P<0.05). Conclusion Oxcarbazepine has more rapid reaction and better curative effect for the treatment of VD patients with agitation of BS at acute stage, while TQHXD have more stable and durable efficacy and less adverse reactions than Oxcarbazepine though its slower onest. TQHXD also can improve the patients’ cognitive. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
